Curto A,
Curto D, Sanchez J. Managing patients taking edoxaban in dentistry.
Systematic review. J Clin Exp Dent.
2017;9(2):e308-11.
doi:10.4317/jced.53431
References
|
1. Falck-Ytter Y, Francis
CW, Johanson NA, Curley C, Dahl OE, Schulman S et al. Prevention of VTE in
orthopedic surgery patients: Antithrombotic Therapy and Prevention of
Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based
Clinical Practice Guidelines. Chest. 2012;141:e278S-325S. |
|
|
PMid: 22315265 PMCid: 3278063 |
|
|
2. Ageno W, Gallus AS,
Wittkowsky A, Crowther M, Hylek EM, Palareti G et al. Oral anticoagulant
therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed:
American College of Chest Physicians Evidence-Based Clinical Practice
Guidelines. Chest. 2012;141(2 Suppl):e44S-88S. PMid: 22315269 PMCid: 3278051 |
|
|
|
|
|
3. Budnitz DS, Lovegrove
MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events
in older Americans. N Engl J Med. 2011;365:2002-12. |
|
|
|
|
|
4. Kato ET, Giugliano RP,
Ruff CT, Koretsune Y, Yamashita T, Kiss RG et al. Efficacy and Safety of
Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI
48 Trial. J Am Heart Assoc. 2016;5:pii: e003432 PMid: 27207971 PMCid: 4889207 |
|
|
|
|
|
5. Giugliano RP, Ruff CT,
Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus
warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-104. |
|
|
|
|
|
6. Bathala MS, Masumoto H,
Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and
mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans.
Drug Metab Dispos. 2012;40(12):2250-5. |
|
|
|
|
|
7. Rognoni C, Marchetti M,
Quaglini S, Liberato NL. Edoxaban versus warfarin for stroke prevention in
non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb
Thrombolysis. 2015;39:149-54. |
|
|
|
|
|
8. Morishima Y, Kamisato
C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban:
comparison of prothrombin time, activated partial thromboplastin time, and
thrombin generation assay. Am J Clin Pathol. 2015;143(2):241-7. |
|
|
|
|
|
9.
Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T,
et al. DU-176b, a potent and orally active factor Xa
inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost.
2008;6:1542-9. |
|
|
|
|
|
10. Ruff CT, Giugliano RP,
Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between
edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an
analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet.
2015;385:2288-95. PMid: 25769361 |
|
|
|
|
|
11. Barrett YC, Wang Z,
Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa
inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb
Haemost. 2010;104:1263-71. |
|
|
|
|
|
12. Lippi G, Favaloro EJ,
Mattiuzzi C. Combined administration of antibiotics and direct oral
anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb
Hemost. 2014;40:756-65. |
|
|
|
|
|
13. Mendell J, Zahir H,
Matsushima N, Noveck R, Lee F, Chen S, et al. Drug-drug interaction studies
of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on
the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J
Cardiovasc Drugs. 2013;13:331-42. |
|
|
|
|
|
14. Mendell J, Chen S, He
L, Desai M, Parasramupria DA. The effect of rifampin on the pharmacokinetics
of edoxaban in healthy adults. Clin Drug Investig. 2015;35:447-53. |
|
|
|
|
|
15. Febbo A, Cheng A,
Stein B, Goss A, Sambrook P. Postoperative Bleeding Following Dental
Extractions in Patients Anticoagulated With Warfarin. J Oral Maxillofac Surg.
2016;74:1518-23. |
|
|
|
|
|
16. Elad S, Marshall J,
Meyerowitz C, Connolly G. Novel anticoagulants: general overview and
practical considerations for dental practitioners. Oral Dis. 2016;22:23-32. |
|
|
|
|
|
17. Tsolka P. Dental
Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants.
Arrhythm Electrophysiol Rev. 2014;3:85-9. |
|
|
|
|
|
18. Mingarro-de-León A,
Chaveli-López B. Alternative to oral dicoumarin anticoagulants:
Considerations in dental care. J Clin Exp Dent. 2013;5:e273-8. |
|
|
|
|
|
19. Johnston S. An
evidence summary of the management of patients taking direct oral
anticoagulants (DOACs) undergoing dental surgery. Int J Oral Maxillofac Surg.
2016;45:618-30. |
|
|
|
|
|
20. Green B, Mendes RA,
Van der Valk R, Brennan PA. Novel anticoagulants - an update on the latest
developments and management for clinicians treating patients on these drugs. J
Oral Pathol Med. 2016;45:551-6. PMid: 27028407 |
|
|
|
|
|
21. Costantinides F, Rizzo
R, Pascazio L, Maglione M. Managing patients taking novel oral anticoagulants
(NOAs) in dentistry: a discussion paper on clinical implications. BMC Oral
Health. 2016;16:5. |
|
|
|
|
|
22. Scott A, Gibson J,
Crighton A. The management of dental patients taking new generation oral
anticoagulants. Prim Dent J. 2014;3:54-8. |
|
|
|
|
|
23. van Diermen DE, van
der Waal I, Hoogstraten J. Management recommendations for invasive dental
treatment in patients using oral antithrombotic medication, including novel
oral anticoagulants. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116:709-16. |
|
|
|
|
|
24. Firriolo FJ, Hupp WS.
Beyond warfarin: the new generation of oral anticoagulants and their
implications for the management of dental patients. Oral Surg Oral Med Oral
Pathol Oral Radiol. 2012;113:431-41. |
|
|
|
|
|
25. Richards D. Guidelines
for the management of patients who are taking oral anticoagulants and who
require dental surgery. Evid Based Dent. 2008;9:5-6. |
|
|
|
|
|
26. Thean D, Alberghini M.
Anticoagulant therapy and its impact on dental patients: a review. Aust Dent
J. 2016;61:149-56. |
|
|
|
|
|
27 Breik O, Cheng A,
Sambrook P, Goss A. Protocol in managing oral surgical patients taking
dabigatran. Aust Dent J. 2014;59:296-301;quiz 401. |
|
|
|
|
|
28. Curtin C, Hayes JM,
Hayes J. Dental implications of new oral anticoagulants for atrial
fibrillation. Dent Update. 2014;41:526-8, 530-1. |
|
|
|
|
|
29. O'Connell JE, Stassen
LF. New oral anticoagulants and their implications for dental patients. J Ir Dent
Assoc. 2014;60:137-43. |
|
|
|
|
|
30. Davis C, Robertson C,
Shivakumar S, Lee M. Implications of Dabigatran, a direct thrombin inhibitor,
for oral surgery practice. J Can Dent Assoc. 2013;79:d74. |
|
|
|
|
|
31. Romond KK, Miller CS,
Henry RG. Dental management considerations for a patient taking dabigatran
etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol.
2013;116:e191-5. |
|
|
|
|
|
32. Kudsi Z, Dalati MH,
Sibai L, Koussayer LT. Management of bleeding disorders in the dental
practice: managing patients on anticoagulants. Dent Update.
2012;39:358-60,363. |
|
|
|
|
|
33. Levy JH, Key NS, Azran
MS. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology.
2010;113:726-45. PMid: 20700042 |
|
|
|
|
|
34. Crowther MA, Warkentin
TE. Bleeding risk and the management of bleeding complications in patients
undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood.
2008;111:4871-9. |
|
|
|
|
|
35. Perry DJ, Noakes TJ,
Helliwell PS; British Dental Society. Guidelines for the management of
patients on oral anticoagulants requiring dental surgery. Br Dent J. 2007;203:389-93. |
|
|
|
|
|
36.
Lopez-Galindo M, Bagán JV. Apixaban and
oral implications. J Clin Exp Dent. 2015;7:e528-34. |
|
|
|
|
|
37. Kerr R, Ogden G, Sime
G. Anticoagulant guidelines. Br Dent J. 2013;214:430. |
|
|
|
|
|
38. Alaali Y, Barnes GD,
Froehlich JB, Kaatz S. Management of oral anticoagulation in patients
undergoing minor dental procedures. J Mich Dent Assoc. 2012;94:36-41. |
|
|
|
|
|
39. Wynn RL. New
antiplatelet and anticoagulant drugs. Gen Dent. 2012;60:8-11. |
|
|
|
|
|
40.
António N, Castro G, Ramos D, Machado A, Gonçalves L, Macedo T et al. The debate concerning oral anticoagulation: whether
to suspend oral anticoagulants during dental treatment. Rev Port Cardiol.
2008;27:531-44. |
|